

OCT. 13. 2003 9:44AM GENAISANCE PHARM.

NO. 191 P. 1

PATENT

Docket No. MWH-0029US

Response (to Office Actions of January 7, 2003, June 26, 2003, and October 7, 2003) filed
October 12, 2003
U.S. Appl. No. 09/856,803


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stephen B. Liggett
Application No.: 09/856,803
Filed: May 25, 2001 (35 U.S.C. § 371 of PCT/US99/27963, filed November 24,
1999, which claims benefit of U.S. Appl. No. 60/109,886, filed November
25, 1998)
Confirmation No.: 3706
Group No.: 1634
Examiner: Myers, C.
For: **POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE β_2 -
ADRENERGIC RECEPTOR**

OFFICIAL

Commissioner for Patents

Certificate of Facsimile Transmission
I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by
facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC
1600, at (703) 372-9306, on 10-12-03


Matthew M. Catlett

RECEIVED
CENTRAL FAX CENTER

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.111

OCT 14 2003

In response to the Office Actions dated January 7, 2003, June 26, 2003, and October 12,
2003 regarding the above-captioned application, please amend the application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.